Intra-Cellular Therapies (NASDAQ: ITCI)
Some price data may be temporarily unavailable.
Intra-Cellular Therapies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intra-Cellular Therapies Company Info
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.
News & Analysis
Why Intra-Cellular Therapies Climbed Tuesday
The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
Strong sales for the company's only marketed therapy piqued investors' interest.
Why Intra-Cellular Therapies Trounced the S&P 500 Today
The biotech notches an extremely convincing first-quarter earnings beat.
Why Intra-Cellular Therapies Took a Big Hit Today
The company is floating at least $400 million worth of its common stock.
Why Intra-Cellular Therapies Was Weak This Week
The company's second-quarter net loss was a bit deeper than analysts expected.
2 Underrated Biotech Stocks to Buy Now
These two biotech companies are safe bargains in today's volatile market.
Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs
Innovation might be worth the high risk up front investment.
2 Top Biotech Stocks to Buy in October
These companies show that specialization can be an excellent competitive strategy.
Valuation
Earnings Transcripts
Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript
ITCI earnings call for the period ending September 30, 2021.
Intra-Cellular Therapies inc (ITCI) Q2 2021 Earnings Call Transcript
ITCI earnings call for the period ending June 30, 2021.
Intra-Cellular Therapies Inc (ITCI) Q1 2021 Earnings Call Transcript
ITCI earnings call for the period ending March 31, 2021.
Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript
ITCI earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.